ArticleJAAD international2026

Tralokinumab for moderate-to-severe atopic dermatitis: A viable option for dupilumab nonresponders.

Christine T Olagun-Samuel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.